相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deciphering Multiple Sclerosis Progression
Virginia Meca-Lallana et al.
FRONTIERS IN NEUROLOGY (2021)
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
Jesus S. Mora et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2020)
Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease
Tengfei Li et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Hyuk Sung Kwon et al.
TRANSLATIONAL NEURODEGENERATION (2020)
Mast Cells in Neurodegenerative Disease
Michael K. Jones et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2019)
Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer's Disease and Multiple Sclerosis
Adham Fani Maleki et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2019)
Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials
Sinje Gehr et al.
EPMA JOURNAL (2019)
Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens
Emanuela Zappulo et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron
Stephen D. Skaper et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2018)
Mast Cells and Innate Lymphoid Cells: Underappreciated Players in CNS Autoimmune Demyelinating Disease
Melissa A. Brown et al.
FRONTIERS IN IMMUNOLOGY (2018)
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study
Olivier Lortholary et al.
LANCET (2017)
Mast cells in neuroinflammation and brain disorders
Erik Hendriksen et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Estimating relative risks in multicenter studies with a small number of centers - which methods to use? A simulation study
Claudia Pedroza et al.
TRIALS (2017)
The role of microglia in multiple sclerosis
Chun Luo et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2017)
Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
Emiliano Trias et al.
JOURNAL OF NEUROINFLAMMATION (2016)
The topographical model of multiple sclerosis A dynamic visualization of disease course
Stephen C. Krieger et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy
Salim Chahin et al.
JOURNAL OF NEUROVIROLOGY (2015)
Mast cells, glia and neuroinflammation: partners in crime?
Stephen D. Skaper et al.
IMMUNOLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
Patrick Vermersch et al.
BMC NEUROLOGY (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
Francois Piette et al.
ALZHEIMERS RESEARCH & THERAPY (2011)
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Patrice Dubreuil et al.
PLOS ONE (2009)
分享论文
